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Gluten related disorders, such as coeliac disease, wheat allergy and baker’s asthma
are triggered by proteins present in food products made from wheat and related cereal
species. The only treatment of these medical illnesses is a strict gluten-free diet; however,
gluten-free products that are currently available in the market can have lower nutritional
quality and are more expensive than traditional gluten containing cereal products. These
constraints have led to the development of gluten-free or gluten-reduced ingredients. In
this vein, a non-GMO wheat flour that purports to contain “65% less allergenic gluten”
was recently brought to market. The present study aims to understand the alteration
of the proteome profile of this wheat flour material. Liquid chromatography-mass
spectrometry was used to investigate the proteome profile of the novel wheat flour,
which was contrasted to a wheat flour control. Using both trypsin and chymotrypsin
digests and a combined database search, 564 unique proteins were identified with
99% confidence. These proteins and the specific peptides used to identify them were
mapped to the wheat genome to reveal the associated chromosomal regions in the
novel wheat flour and the mixed wheat control. Of note, several ω- and γ-gliadins,
and low-molecular weight glutenins mapping to the short arm of chromosome 1, as
well as α-gliadins from the chromosome 6 short arm were absent or expressed at
lower levels in the novel wheat variety. In contrast, the high-molecular weight glutenins
and α-amylase/trypsin inhibitors were notably more abundant in this variety. A targeted
quantitation experiment was developed using multiple reaction monitoring assays to
quantify 359 tryptic and chymotryptic peptides from gluten and related allergenic proteins
revealing a 33% decrease of gluten protein content in the novel wheat flour sample in
comparison to mixed wheat control. However, additional mapping of known allergenic
epitopes showed the presence of 53% higher allergenic peptides. Overall, the current
study highlights the importance of proteomic analyses especially when complemented
by sequence analysis and epitope mapping for monitoring immunostimulatory proteins.
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INTRODUCTION
Wheat products account for some 20% of dietary calories and
protein ingested globally (1). However, in susceptible people
wheat proteins can elicit a range of health disorders including
coeliac disease (CD), wheat allergy (WA), and non-coeliac
wheat sensitivity (NCWS). The allergenic wheat proteins that
cause these adverse immune reactions have been mapped to
specific genes by The International Wheat Genome Sequencing
Consortium (IWGSC) and collaborators (2, 3). CD is caused
when dietary gluten reaches the small intestine of genetically
predisposed individuals and stimulates an autoimmune response
leading to localized damage and subsequent symptoms (4).
WA, as well as baker’s asthma (BA) and wheat-dependent
exercise induced anaphylaxis (WDEIA), involve an IgE-mediated
immune response to wheat proteins that are either ingested
as food or occur via skin contact or inhalation. While these
disorders can be triggered by gluten proteins, BA typically has
a non-gluten protein trigger (5, 6). NCWS is diagnosed when
symptoms develop in response to cereal grain consumption, but
serological testing is negative for both an autoimmune response
and the IgE-mediated allergic response, which contraindicates
CD and WA, respectively (4, 7). While the term “non-celiac
gluten sensitivity” has a history of use (8), NCWS better
reflects the non-gluten wheat proteins (9) or non-protein wheat
components like FODMAPs (10) that elicit similar symptoms (7).
CD is estimated to afflict ∼0.7–1.4% of the global population
(11, 12), WA some 0.33–0.75% in adults (13–15), and NCWS
being more variable but with prevalence estimated between 0.5
and 13% (16, 17). While gluten proteins are established antigens
to those with CD and also contribute to various allergies, non-
gluten wheat proteins are potential allergens and antigens capable
of causing WA, BA, NCWS, as well as CD (3, 6, 18).
The only effective treatment for these wheat-related immune
disorders is the exclusion of wheat and related crop species from
the diet. This adds to demand for “gluten free” foodstuffs that
resemble traditional wheat products, however wheat is replaced
by substitute ingredients that contribute starch but without
gluten or other cereal proteins. The absence of gluten proteins,
however, can affect the consistency, texture, or taste of gluten-
free products, and the substitute ingredients typically come at a
higher cost and require recipe alterations (19).
Several approaches have aimed at reducing the gluten content
while retaining the health benefits of whole grains or maintaining
the unique functionality of cereal grains. One approach is to use
ethyl methanesulfonate (EMS) mutagenesis to produce random
mutations in genetic material by nucleotide substitution. EMS is
often used as the technology base for “Targeting Induced Local
Lesions in Genomes” (TILLING) which has proven effective at
targeting key wheat enzymes to improve starch composition
(20). It has been applied to wheat gluten genes (21), but is
challenged by the sheer number of potential allergens and the
fact that even low levels of expressed gliadins can elicit CD (22).
In barley, ultra-low gluten levels (<5 mg/kg) were achieved in
the variety Kebari R© by using traditional breeding techniques
to combine mutagenesis-derived barley varieties with decreased
hordein content and composition (23, 24). Efforts to develop
a low-allergen wheat variety have targeted genes that either
exhibit a large immune response directly (25), or that conduct
epigenetic regulation of downstream gluten protein genes (26),
and have also made use of natural null-allele variants (27),
CRISPR-Cas9 (28), and RNAi (29). A common phenotype is that
downregulation of one or a subset of gluten protein encoding
genes is accompanied by the compensatory upregulation of
alternate storage proteins (30–34), with a change in technological
properties (35). However, technology to characterize gluten
in wheat products is the subject of ongoing research (36),
as is the targeted removal of CD reactive epitopes from
wheat (37).
Recently, a reduced gluten product was released that claims
to be a non-GMO wheat variety which contains “65% less
allergenic gluten than traditional flour.” It is clarified that the
product is “developed for those with sensitive stomachs who
don’t have gluten or wheat allergies, but who want to reduce
the amount of gluten in their diets” (38) and was developed
using wheat prolamin box binding factor (PBF) mutants (21,
US patents 9,150,839, 10,412,909, and 10,750,690). There are no
reports of the proteome and overall characteristics of proteins
present in the reduced gluten flour in comparison to commercial
wheat varieties.
Wheat has more than 800 genes with potentially allergenic
domains, and some 356 genes encoding reference food allergens
are included in the “IWGSC v1.0 reference allergen map” (3).
This includes gliadins (including α-, β-, γ-, and ω-subtypes) and
glutenins (including low molecular weight (LMW) glutenins and
high molecular weight (HMW) glutenin subunits), as well as
avenin-like proteins (ALPs), α-amylase/trypsin inhibitors (ATIs),
and lipid transfer proteins (LTPs) (3). The gluten proteins contain
specific epitopes that are deamidated, recognized, and presented
by MHC-II antigen presenting cells in the gastrointestinal
tract, in doing so initiating the autoimmune response that
characterizes CD (39). The canonical gluten proteins, the gliadins
and glutenins, together make up some 80% of the protein content
in the wheat endosperm, and the most potent contributors to CD
toxicity are the chromosome 6D α-gliadins and chromosome 1D
ω-gliadins (ω 1,2 sub-type), followed by the LMW glutenins and
γ-gliadin (40). It is therefore important to precisely characterize
protein groups and epitopes when quantifying “allergenic gluten”
in new products. This present study aimed to understand the
alterations to the proteome in this reduced gluten wheat product
using LC-MS/MS in comparison to a mixed wheat control.
MATERIALS AND METHODS
Sample Preparation
GoodWheatTM (GW) white bread wheat flour was purchased
directly from Arcadia Bioscience (Davis, CA, USA). Replicates
of GW and of a mixed-wheat (MW) control flour sample
were weighed out in quadruplicate. The MW control consisted
of equal parts of flour from wheat cultivars: Alsen, Xiayan,
Pastor, Westonia, Baxter, Chara, Yitpi, AC Barrie, and Volcania;
selected to represent the diversity of wheat used in commercial
production. Gluten proteins were specifically enriched from the
wheat using an isopropanol/dithiothreitol (IPA/DTT) solvent as
described previously (41). Flour (50mg) was weighed into a
1.5mL micro-tube and 500 µL (10 µL/mg) of 55% IPA/2% DTT
Frontiers in Nutrition | www.frontiersin.org 2 August 2021 | Volume 8 | Article 705822
Nye-Wood et al. Gluten Detection by Proteomics
was added with vortex mixing until the flour was thoroughly
combined with the solvent. The tubes were then sonicated
for 5min at room temperature and incubated in a thermo-
mixer (400 rpm, 30min, 50◦C). The tubes were centrifuged
for 15min at 20,800 ×g. The solutions were centrifuged for
15min at 20,800 ×g. Protein extracts (100 µL) were added
to 10 kDa molecular weight cut off filters (Merck, Bayswater,
Australia). The protein on the filter was washed twice with a
buffer consisting of 8M urea in 0.1M Tris-HCl (pH 8.5) with
centrifugation for 15min at 20,800 ×g. Iodoacetamide (25mM;
100µL) prepared in 8M urea and 100mM Tris-HCl was added
to the filters for cysteine alkylation with incubation in the dark
for 20min prior to centrifugation for 10min at 20,800 ×g. The
buffer was exchanged with 100mM ammonium bicarbonate (pH
8.0) by two consecutive wash/centrifugation steps. The filters
were transferred to fresh collection tubes and digestion enzyme,
either trypsin or chymotrypsin (Promega, NSW, Australia),
was prepared as 10µg/mL in 100mM ammonium bicarbonate,
50mM calcium chloride and 200 µL was added to each filter
with incubation for 16 h at 37◦C. The filters were centrifuged
for 15min at 20,800 ×g. The filters were washed with 200 µL
of 100mM ammonium bicarbonate, and the combined filtrates
were subsequently lyophilized.
Discovery Proteomics
The digested samples were reconstituted in 100 µL of 1% formic
acid and the peptides (1 µL) were chromatographically separated
on an Ekspert nanoLC415 (Eksigent, Dublin, CA, USA) coupled
to a TripleTOF 6600MS (SCIEX, Redwood City, CA, USA). The
peptides were desalted for 5min on a ChromXP C18 (3µm,
120 Å, 10 × 0.3mm) trap column at a flow rate of 10 µL/min
of 0.1% formic acid and separated on a ChromXP C18 (3µm,
120 Å, 150 × 0.3mm) column at a flow rate of 5 µL/min. The
solvents used were (A) 5% DMSO, 0.1% formic acid, 94.9% water
and (B) 5% DMSO, 0.1% formic acid, 90% acetonitrile, 4.9%
water. A linear gradient from 3 to 25% solvent B over 68min
was employed followed by 25–35% B over 5min, an increase
to 80% B over 2min, a 2min hold at 90% B, return to 3%
B over 1min, and 8min of re-equilibration. The eluent from
the HPLC was directly coupled to the DuoSpray source of the
TripleTOF 6600MS. The ionspray voltage was set to 5,500V; the
curtain gas was set to 138 kPa (20 psi), and the ion source gas
1 and 2 (GS1 and GS2) were set to 103 and 138 kPa (15 and
20 psi). The heated interface was set to 150◦C. The discovery
data files of individual technical replicates of either trypsin or
chymotrypsin digested GW and MW samples were searched
using ProteinPilot v5.0.3 with Paragon Algorithm (SCIEX)
against a FASTA file consisting of Triticeae tribe proteins from
UniProt-KB [accessed 02/2021 supplemented with additional
translated gene models from the IWGSC RefSeq v1 Assembly (2),
as well as those listed on the common Repository of Adventitious
Proteins (thegpm.org/crap)]. The FASTA file contained 817,698
protein sequences.
Targeted Proteomics
Reduced and alkylated tryptic and chymotryptic peptides were
chromatographically separated on an Exion LC-40AD UHPLC
system (SCIEX) and analyzed on a 6,500+ QTRAP mass
spectrometer (SCIEX). Data acquisition was achieved using
scheduled multiple reaction monitoring (sMRM) scanning
experiments using a 60 s detection window for each MRM
transition and a 0.3 s cycle time.
To build the MRM method, a FASTA file containing all
identified proteins was imported into Skyline (42), all fully
tryptic peptides sized between 6 and 30 amino acids were
selected, and repeated peptides removed. All fully chymotryptic
peptides between 6 and 30 amino acids were selected in
independent experiments. Initially, five transitions were selected
per peptide in an unscheduled MRM assay and assessed on
both GW and MW samples. Those peptides where at least
three transitions reproducibly co-eluted at the expected retention
time (RT) without interference were then selected for inclusion
in scheduled MRM assays. These were divided across several
separate transition lists, such that all data was recorded with a 60 s
detection window and maximum cycle time of 0.3 s. Precursor
ions where three or more transitions had consistent RT, intensity
over 1,000 cps, and a signal to noise ratio (S/N)>5 were kept and
the three most intense transitions were selected for subsequent
quantitative experiments. In this way, a total of 768 tryptic and
175 chymotryptic peptides that were unique to one protein were
monitored, as well as 263 tryptic and 109 chymotryptic peptides
that were present inmore than one protein. Data was collected on
four technical replicates of GW and MW. Peptide peak area data
was exported from Skyline and analyzed (Graphpad Prism v8).
To quantify the relative abundance of individual gluten
protein groups, peak areas of both unique and non-unique
peptides were summed. Proteins were mapped to the wheat
genome using the tBLASTn function of CLC Main Workbench
v20.0.4 (Qiagen, Denmark), and multiple proteins mapping
to the same gene were interpreted as different alleles of the
same gene. Quantified MRM peptides were then allocated
to protein groups according to the proteins in which they
were found. Peptides occurring in proteins from multiple
groups were labeled Multiple/Mixed. The significance and fold
change of these protein groups were graphed using VolcaNoseR
software (43).
A high sequence similarity between gluten proteins meant
many peptides were observed that were common to multiple
gluten proteins, making it impossible quantify all proteins using
unique peptides. To overcome this, peptides quantified via MRM
were allocated to gluten protein groups that were quantified
using unique peptides for GW and MW, revealing the relative
abundance of protein groups in these samples. To do this, all
peptides quantified were mapped to the wheat genome (2),
and using a combination of sequence alignments, the presence
of Pfam domains (PF13016, PF03157, PF00234), and manual
checking of the matching proteins were allocated to one of
the following protein groups: α-gliadins, ALPs, ATIs, γ-gliadin,
HMW-GSs, LMW-GSs, and ω-gliadins. Where the proteins had
two or more peptides from multiple protein groups they were
defined as “mixed.” While the ATIs and ALPs are not canonical
gluten proteins, several of the ALPs can function as nutrient
reservoir proteins, and the ATIs exhibit some allergenicity
making them relevant to this investigation.
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To quantify protein groups, the monitored peptides were
mapped to the identified gluten protein sequences and non-
gluten protein families with immune-reactive properties using
100% sequence matching in the Motif search algorithm in
CLC Genomic Workbench v21.0.3 (Qiagen, Denmark), and
group specific peptides were identified. Quantitative data on
all chymotryptic and tryptic peptides were combined, and the
abundance of each peptide in each replicate was normalized to
the average seen across all replicates from both GW and MW.
Graphs were generated in Graphpad Prism v8.
Gene Enrichment Analysis
GO enrichment analysis was performed to test for the
downregulation of certain classes of proteins in GW. Those
proteins present in both GW andMWwere excluded so that only
proteins unique to GW or MW were analyzed for enriched GO
terms. GW- or MW-specific proteins were then mapped to the
wheat genome using CLC Genomic Workbench v21.0.3 (Qiagen,
Denmark), and lists of their corresponding wheat gene identifiers
were pasted into g:Profiler (biit.cs.ut.ee/gprofiler/gost) for GO
overrepresentation analysis.
Epitope Mapping
The peptides identified at 1% FDR in discovery proteomics
were searched for known CD related T cell epitopes [Ludvig
M (44)], baker’s asthma, and wheat allergy related epitopes
collected from the Immune Epitope Database and Analysis
Resource (www.iedb.org) using the Motif search algorithm in
CLC Genomic Workbench v21.0.3 (Qiagen, Aarhus, Denmark).
Additionally, peptides recognized by commercial ELISA kits
using R5 and G12 monoclonal antibodies were also mapped to
the protein and peptide sequences. Hits with 100% sequence
identity were kept in the analysis. The peptides monitored in
MRM assays were also mapped to the same protein list, and the
overlap between CD epitopes and the monitored peptides were
determined. Monitored peptides that contained an entire epitope
in their sequence were selected and quantified in GW andMW to
give a relative measure of potential immune reactivity.
Protein and ELISA Measurement
Protein estimations were performed using a Coomassie dye
binding protein assay using Bradford reagent (Sigma-Aldrich,
St Louis, USA) following the manufacturer’s instructions.
Measurements were made at 595 nm using a Varioskan LUX
microplate reader (Thermo Scientific, Scoresby, Australia).
Bovine serum albumin (BSA) standard was used in the linear
range 0.125–1.5 mg/mL.
Diluted wheat extracts were analyzed by sandwich ELISA
using the Ridascreen Gliadin (R-Biopharm, Darmstadt,
Germany). The analytical protocols provided by the kit
manufacturer were strictly followed. Each of the samples
was extracted using the extraction Cocktail (R7006/R7016,
R-Biopharm) recommended by the manufacturer for optimal
gluten extraction and measured on the using Varioskan LUX
microplate reader (Thermo Scientific) in duplicate on a single
ELISA plate alongside the supplied standards (representing a
gluten concentration of 5–80 mg/kg). The results of absorbance
TABLE 1 | Numbers of distinct proteins and of gluten and ATI proteins identified at
99% confidence in trypsin and chymotrypsin data.
Trypsin Chymotrypsin Combined
GW total 285 139 360
GW gluten 76 75 126
α-gliadin 6 11 15
ATI 24 16 29
Avenin-like protein 11 5 12
γ-gliadin 11 8 18
HMW-GS 13 9 17
LMW-GS 11 23 32
ω-gliadin 0 3 3
GW non-gluten 209 64 234
MW total 360 151 448
MW gluten 73 93 138
α-gliadin 6 16 19
ATI 27 19 36
Avenin-like protein 9 6 10
γ-gliadin 10 16 23
HMW-GS 9 9 13
LMW-GS 11 23 32
ω-gliadin 1 4 5
MW non-gluten 287 58 310
GW and MW combined 440 179 541
readings were analyzed according to the kit manufacturer’s
instructions using cubic polynomial regression for the standard
curve. The data analyses were performed using Microsoft Excel.
RESULTS
Discovery Proteomics
To identify the proteins in the GW and MW samples, combined
database searches were performed on the discovery proteomics
datasets. The numbers of distinct proteins identified at 1% global
false discovery rate (FDR) excluding identifications against the
common contaminants (cRAP database) are summarized in
Table 1. This information is generated from the reports available
at https://doi.org/10.25919/fr8e-k267, processed with the Protein
Alignment Template v3.002 beta (SCIEX) and manual curation.
Of the 541 proteins identified in both GW and MW (Table 1),
more were identified in tryptic digests (440) than chymotryptic
digests (179). Greater representation of α- and γ-gliadins and
LMW-GS was achieved using chymotryptic digests, while more
ATIs, ALP-derived, and non-gluten proteins were identified in
tryptic digests (Table 1).
Considering trypsin and chymotrypsin data together enables
a more complete comparison of the GW and MW proteomes.
Together, there were 360 distinct proteins identified in GW and
448 in MW, with an overlap of 267. The higher number in
MW reflects the genetic diversity of the multiple wheat varieties
that are present. In GW, 126 of identified proteins were gluten-
like proteins (35%) and in MW this number was 138 (31%).
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FIGURE 1 | Summary of total and gluten-like proteins identifications at 1%
FDR and their corresponding chromosomal locations. (A) Venn diagram
showing the total number of proteins detected within the GW and MW
datasets. (B) Detected gluten proteins in MW and GW. (C) Locations of genes
for detected proteins on wheat chromosomes 1A, 1B, and 1D.
Notably, the GW and MW proteomes share 99 (60%) of the
165 detected gluten proteins. The numbers of proteins identified
are compared in Figures 1A,B. To identify the chromosomal
position of these proteins within the wheat genome protein,
sequences were mapped to the IWGSC wheat genome assembly
version 1 (2), and the number of peptides observed per 1 million
base pairs (Mb) bins was determined. This revealed clusters
of detected proteins in all known storage protein gene loci
regions of the genome, corresponding to γ- and ω-gliadins,
LMW-GS, and HMW-GS (3) on chromosome group 1 and α-
gliadins on chromosome group 6. Figure 1C shows the location
of the peptides detected superimposed on chromosomes 1A,
B, and D, respectively. Though non-gluten proteins were also
detected across all wheat chromosomes, there were no large-
scale chromosome region changes observed in GW and MW,
indicating the potential for gene expression of gluten proteins
in GW.
Targeted Proteomics
To investigate the quantitative changes across GW and MW
wheat samples, LC-MRM-MS-based quantitative assays were
developed for all peptides confidently identified in the discovery
proteomics experiment (Figure 2). A total of 189 tryptic peptides
and 170 chymotryptic were targeted. While 84 tryptic and 55
chymotryptic peptides were uniquely present, i.e., in only one
protein isoform, many of the peptides monitored by MRM
occur in multiple protein isoforms and therefore reflect the
relative abundance of more than one protein. While LC-MRM-
MS reveals peptide relative abundance, using this information
to quantify proteins by combining the constituent peptides is
confounded by both the presence of repeated peptides and
differential ionization efficiency of various peptides.We therefore
categorized peptides into groups that reflect the abundance of
major allergen types and did not quantify specific proteins. This
revealed the fold-change and significance of tryptic (Figure 2A)
and chymotryptic peptides (Figure 2B) peptides between GW
and MW. HMW-GS and ATI peptides tend to be higher in GW
than MW, and many tryptic “non-gluten” peptides are higher in
GW. Similarly, many LMW-GS, ALP, and α-gliadin peptides are
lower in GW than MW.
The normalized peak area for all peptides belonging to
each protein group were then summed to compare the overall
abundance of each protein group (Figure 3). Importantly, GW
showed significantly lower abundance of LMW-glutenins, α-
gliadins, and γ-gliadins, but showed an increase in HMW-
glutenins relative to MW. GW also showed significant decreases
in ALPs and increases in ATIs. Changes in net ω-gliadin
abundance were not significant. The net change in canonical
gluten content can be obtained by adding together the gliadins
and glutenins (LMW-GS, HMW-GS, α-, γ-,ω-gliadins), showing
that GW has 67% the relative gluten protein abundance as MW
(Figure 3B).
Gene Set Enrichment Analysis
To understand the enrichment of protein classes within
the individual wheat samples, GO enrichment analysis was
performed using g:Profiler on those proteins detected with
a fold change ≥2 in MW and GW as shown in Figure 2.
Proteins in MW showed predominant enrichment for nutrient
reservoir activity (GO:0045735, Figure 4A). GW proteins
showed enrichment of several classes of enzyme inhibitor and
regulators, as well as enrichment of proteins localizing to
the Extracellular Region (GO:0005576) cellular compartment
indicating the compensation mechanism for the expression
of non-gluten proteins. There was no enrichment of nutrient
reservoir activity (Figure 4B).
Epitope Mapping
To explore the potential immune reactive nature of proteins
detected in GW compared to those in MW, peptides identified
in the discovery data that contained full-length immune reactive
epitopes were quantified (Figure 5). Known immunogenic
regions within quantitated MRM peptides are quantified,
including HLA-DQ T cell epitopes for CD patients (Figure 5A),
baker’s asthma epitopes (Figure 5B), and wheat allergy-related
epitopes (Figure 5C). It should be noted that these represent
a small subset of the known immune reactive epitopes. The
discovery analysis results (Supplementary Table 1) indicate the
presence of additional epitopes that were not quantified with
MRM. There were six complete HLA-DQ T cell epitope
sequences observed in a total of 25 peptides, nine BA epitopes in
12 peptides, two WA epitopes in 16 peptides, and one WDEIA
epitope in one peptide. Overall, HLA-DQ reactive epitopes in
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FIGURE 2 | Volcano plots showing quantified tryptic (A) and chymotryptic (B) peptides in GW and MW samples colored according to gluten group. A fold-change of
2 is indicated by the dashed vertical lines [Log2(FC) = ±1]. Peptides above the horizontal dashed line have a significant change in abundance between GW and MW
(p-value <0.01 [–log10(p) >2].
GW were present at 67% the relative abundance of MW. BA-
reactive epitopes were also more abundant in GW at 180% that
of MW.WA-reactive epitopes were also more abundant in GW at
379% the level seen in MW. Only one wheat dependent exercise-
induced anaphylaxis epitope was observed, which was notably
lower in GW at 17.7% the level seen in MW.
The protein content of MW and GW were evaluated and
did not show a significant difference at 0.84 and 0.88 mg/mL,
respectively. The gluten content was also evaluated by R5 ELISA
and it was interesting to note that GW revealed a 39% higher
gluten content than MW, an unexpected result given the overall
decrease in gluten peptides detected by LC-MS.
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FIGURE 3 | Relative abundance of different gluten or ATI protein groups (A). Quantitation was performed based on all detectable peptides from proteins classified to
these groups. Error bars indicate SEM, and significant differences are indicated by asterisk. Adding together the LMW and HMW glutenins, and α-, γ-, ω-gliadins gives
the net gliadin and glutenin content (B) which equated to GW having an estimated 67% of the gluten content of MW (dotted line).
FIGURE 4 | GO enrichment analysis of proteins showing ≥2-fold increase in: MW (A); or GW (B).
DISCUSSION
The current study used complementary high sensitivity LC-
MS techniques to identify gluten proteins and to monitor the
relative abundance of gluten and allergenic wheat proteins
in a recently developed wheat product (GoodWheat, GW) in
comparison to a wheat sample mixed from equal amounts of
nine commercial cultivars (Mixed wheat, MW). Peptides from
gliadin and glutenin proteins were present in GW at 67% of the
abundance of the MW control, indicating an average decrease of
33% (Figure 3B). This is complemented by our analysis of intact
HLA-DQ reactive epitopes in the monitored peptides which
were 67.3% as abundant in GW as MW (Figure 5A). While this
may reduce but not remove the antigen content of GW, it is
accompanied by an increase in peptides known to be related to
Baker’s asthma and wheat allergy, at 180 and 379%, respectively.
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FIGURE 5 | Relative abundance of immune reactive epitopes in peptides
quantified in MRM assays, reported as mean and standard error. Epitope
sequences are highlighted in bold within the peptide sequence: (A) Coeliac
disease HLA-DQ reactive epitopes; (B) Bakers’ asthma; (C) Wheat Allergy
plus peptide QQQQQQQQILQQILQQQLIPCR which contains the epitope
QILQQQLIPC antigenic for wheat-dependent exercise induced anaphylaxis.
When calculating the total, duplicate peptides where multiple epitopes were
detected were only counted once.
The overlap between immunogenic DQ epitopes with peptides
detected in discovery data, and quantified in MRM is presented
in Supplementary Table 1. While the use of LC-MRM-MS in this
work enabled the quantitation of gluten proteins and highlights
its utility in grain protein research with specific reference to
gluten, future studies should focus on using complementary
extraction buffers to understand more about changes in the GW
grain proteome.
In contrast to the MRM analysis that revealed an overall
lower gluten content in GW than MW (Figure 3), the R5 ELISA
estimate of gluten content revealed a gluten content∼39% higher
in GW than MW. The slightly elevated protein content (5%)
in GW compared to MW would account for a minority of the
observed difference. The elevated ELISA measurement likely
reflects an overall increase in the ratio of R5 epitope per unit of
protein. The choice of reference material, in particular the ratio
of gliadin to glutenin, is known to affect measurements of gluten
by ELISA even in simple food matrices (45), and kits that use
different primary antibodies will yield different measurements
of gluten (46) because of the specificities and sensitivities of the
primary antibody (47). Future analyses should investigate the
gluten content of GW using alternative ELISA kits or gluten
protein quantitation employing fractionation (RP-HPLC or size-
exclusion chromatography) protocols.
Important trends were seen in specific gluten protein types
(Figures 2, 3), as the LMW-GSs, α-, and γ-gliadins are lower
in GW, while the HMW-GSs were significantly more abundant.
HMW glutenins contribute more to bread’s elastic properties
than other gluten proteins due to their relative size and ability
to form large polymers (48). Their higher relative abundance
in GW indicates that they in part compensate for the lower
abundance of gliadins and LMW glutenins (49). Additionally,
the level of immune response elucidated by HMW glutenins in
CD is significantly lower compared to the α-, γ-, and ω-gliadins
and LMW glutenins (40), making their increase less relevant
to CD, however it has important implications for WA and BA.
Along with ATIs, which were also significantly higher in GW,
the higher HMW glutenin content in GW brings more allergenic
epitopes related to WA and BA. This is reflected in Figure 5 as
the allergenic epitopes recognized by different B and T cell types
are increased by an overall 53.5%.
Interestingly, the ALPs were also present in significantly lower
amounts in GW than MW. While named for their resemblance
of oat avenins (50), these seed storage proteins share sequence
similarity and secondary function with γ-gliadins and LMW
glutenins (51). They contribute both to allergenicity (52) and
bread dough quality (53), and contain one or two gliadin
(PF13016) domains. ALPs also contain CD-related B cell epitopes
(3), and their downregulation is important for CD toxicity.
The symmetry of the volcano plot (Figure 2) indicates the
net decrease in gluten protein and ALP content is accompanied
by compensatory expression of other proteins within the grain.
GO enrichment analysis of the GW proteome revealed enzyme
inhibitors and regulators that are enriched in GWwhich was also
confirmed by the gene set enrichment analysis showing cysteine-
rich proteins are overrepresented in the upregulated proteins in
GW. Most of these proteins have a defense related function and
were upregulated in lieu of proteins with a canonical “nutrient
reservoir activity” GOMF annotation (Figure 4).
Our proteogenomic analysis indicates that there is no evidence
of large-scale chromosome deletions or absence of storage
protein gene clusters (Figures 1B,C) on chromosome group
1 and 6 in GW. While antibody-based assays or classical
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Osborne fractionation were not performed and thus represents
a limitation of the present work, gluten proteins were present
in both GW and MW and simply expressed at different levels
(Figure 3). This would suggest the novel GW variety expresses
less gluten proteins due to gene regulation at a transcriptional or
post-transcriptional level. There are several known mechanisms
implicated in seed development and gluten protein expression
that may be at play. One is the LYS3 gene that encodes
the transcription factor Prolamin Binding Factor (PBF). PBF
is expressed early in seed development, and suppresses seed
growth by reducing the expression of developmental and starch
metabolism genes (54). Wheat lys3 mutants have been reported
to contain lower levels of gliadins and LMW-GSs (21), which
matches our results as shown in Figure 4. A barley variety
with lys3a mutation causing it to not express C-hordein (a
class of barley gluten) was used in a breeding program to
derive an “ultra-low gluten” barley variety (30, 55), showing
it is compatible with selective breeding. These low-gluten PBF
mutant lines exhibit increased expression of lysine-rich genes
that are otherwise related to developmental processes during
germination (30). While it is possible that GW uses lys3
mechanisms to regulate gluten protein expression, using solely
the proteomic information presented in this study we cannot
conclusively determine the targeting of lys3 regulation.
In conclusion, the use of discovery and targeted proteomics-
based experiments has enabled the detection and quantitation
of gluten and additional allergenic proteins present in the GW
and MW samples. This study revealed a 33% decrease in gluten-
like proteins in GW and the compensatory expression of non-
gluten proteins within MW samples that tend to have enzyme
inhibitor or regulator activity GO terms. This study affirms that,
as stated by the manufacturer, GW is not compatible with a
gluten-free diet. Epitope mapping revealed a reduction in gluten
protein-specific epitopes; however, there was an increase in
epitopes related to baker’s asthma and wheat allergy in GWwheat
in comparison to MW. Additionally, the chromosomal level
analysis of detected proteins showed no significant differences
between GW and MW. Future studies focusing on integrating
LC-MS/MS results with clinical measurements would be needed
to investigate the nutritional benefits of GW. Overall, the current
study exemplifies the use of proteogenomic approaches as a tool
to explore the safety and/or health benefits of wheat varieties
targeted toward consumers with wheat-related disorders.
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